Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1
Publication Type:
Journal Article
Authors:
Naggie, S.;
Cooper, C.;
Saag, M.;
Workowski, K.;
P J Ruane;
Towner, W.J.;
Marks, K.;
Luetkemeyer, A.;
Baden, R.P.;
Sax, P.E.;
E J Gane;
Santana-Bagur, J.;
Stamm, L.M.;
Yang, J.C.;
German, P.;
Dvory-Sobol, H.;
Ni, L.;
Pang, P.S.;
J G McHutchison;
Stedman, C.A.;
Morales-Ramirez, J.O.;
Brau, N.;
Jayaweera, D.;
Colson, A.E.;
Tebas, P.;
Wong, D.K.;
D. Dieterich;
M S Sulkowski;
ION-4 InvestigatorsSource:
N Engl J Med, Volume 373, Issue 8, p.705-713 (2015)
Keywords:
Alabama,
Antiretroviral,
Baltimore,
Boston,
California,
Canada,
Cities,
Diarrhea,
efavirenz,
emtricitabine,
England,
Fatigue,
Genotype,
genotype 1,
HCV,
Headache,
Health,
hepatitis,
Hepatitis C,
hepatitis C virus,
Hiv-1,
Human,
Israel,
Liver,
Los Angeles,
Medicine,
methods,
New England,
New York,
New Zealand,
NS5A inhibitor,
Patients,
Philadelphia,
Puerto Rico,
raltegravir,
Research,
rilpivirine,
San Francisco,
sofosbuvir,
sustained virologic response,
tenofovir,
therapy,
treatment,
Universities,
Veterans
